Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024GlobeNewsWire • 05/30/24
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismGlobeNewsWire • 05/14/24
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialGlobeNewsWire • 05/13/24
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024GlobeNewsWire • 05/09/24
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024GlobeNewsWire • 04/25/24
United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismGlobeNewsWire • 04/24/24
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?Market Watch • 04/10/24
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024GlobeNewsWire • 03/04/24
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 02/15/24
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/07/24
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024GlobeNewsWire • 01/31/24
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismGlobeNewsWire • 01/31/24
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External InvestorsGlobeNewsWire • 01/29/24